Navigation Links
Researchers discover new approach for identifying smokers at highest risk for developing lung cancer
Date:4/7/2010

(Boston) Researchers from Boston University School of Medicine (BUSM) in collaboration with investigators at the University of Utah, have discovered a new approach for identifying smokers at the highest risk for developing lung cancer. The findings, which appear in the April 7th issue of Science Translational Medicine, will allow the researchers to use a genomic approach to prevent lung cancer in these individuals and to personalize cancer chemoprophylaxis and therapy.

Cigarette smoke is the dominant cause of lung cancer in the United States, accounting for an estimated 90 percent of all cases. While only 10-20 percent of smokers develop lung cancer in their lifetime, there are currently no tools available to identify which of the approximately 90 million current and former smokers in the U.S. are at the highest risk. Unfortunately, diagnosis is most often made at a very advanced stage where treatment is largely ineffective. The damage caused by cigarette smoke, however, is not limited solely to the lung, but rather constitutes a 'field of injury' throughout the entire respiratory tract that is exposed to the toxin. Consistent with this idea, study lead author Avrum Spira, MD, MSc, chief of the section of computational biomedicine in the department of medicine at BUSM and his colleagues, previously developed a gene expression-based biomarker measured in the cytologically normal bronchial airway epithelium that reflects an individual's physiologic response to smoking and distinguishes smokers with and without lung cancer. Although this biomarker is successful at diagnosing lung cancer, it does not identify the signaling pathways underlying these gene expression changes.

Using a novel gene-expression based approach to define oncogenic pathway signatures, the researchers, in collaboration with Dr. Andrea Bild at the University of Utah, have now discovered that the expression of genes belonging to one specific cancer-related pathway, PI3K, are activated in the cells that line the airway of smokers with lung cancer. This gene expression activity in the normal cells of the proximal airway precedes the development of lung cancer and may be reversed with a specific chemopreventive agent (myo-inositol) that targets this pathway.

"This finding is significant as these cells can be obtained in a relatively non-invasive fashion from the airway of smokers at risk for lung cancer, and does not require invasive sampling of lung tissue where lung tumors normally arise," said Spira, who is also an associate professor medicine and pathology at BUSM.

The BUSM researchers then went on to validate their findings by measuring the biochemical activity of this pathway in the airway epithelial cells from an independent group of smokers with and without lung cancer. "We found that this PI3K pathway gene expression activity is decreased in the airway of high-risk smokers who had regression (or improvement) of their premalignant lesions following treatment with a potential lung cancer chemopreventive agent known as myo-inositol, and demonstrated that myo-inositol inhibits the PI3K pathway in lung cancer cell lines," he added.

According to the researchers, the data suggests that measuring this airway gene expression activity can help determine which specific cancer pathways have been deregulated within an individual smoker, allowing one to tailor a specific drug that will target the pathway to reduce that individual's risk of lung cancer. "This represents a critical advance in the field of lung cancer prevention as there are currently no effective strategies for lung cancer prevention among high risk smokers. Our work has the potential to help address the enormous and growing public health burden associated with lung cancer, the leading cause of cancer-related death among men and women in the US and the world," added Spira.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers aim for consensus on measuring the impact of visual impairment
2. Researchers Boost Post-Heart Attack Survival in Mice
3. Researchers quantify benefits of minimally invasive removal of hard-to-reach tumors
4. Researchers design self-test for memory disorders
5. Researchers identify potential new target for treating hepatitis C
6. Researchers Identify 2 Genes Linked to Fatty Liver Disease
7. NIA researchers find gene to explain mouse embryonic stem cell immortality
8. Researchers discover fundamental step in immune-system development
9. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
10. SRI International Researchers to Present Work on Early Detection Tool for Neglected Tropical Diseases at 2010 American Chemical Society (ACS) Meeting
11. Researchers find new chemotherapy combination shows promise in endometrial cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), creator ... tool, and the Cancer Patient Education Network (CPEN), an independent professional organization that ... new strategic alliance. , As CPEN’s strategic partner, HLI will help support ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical ... to physician colleagues, skilled nursing facility medical directors and other clinicians at various ... Wound Care." , "At many of these conferences we get to educate other ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated ... latest FDA requirements, which stipulates new criteria regarding medical device manufacture ... Medical ID jewelry such as Medical ID Bracelets, can rest assured ... of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process ...
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance ... a medical-grade battery-powered display stand specifically designed for endoscopy environments. An ... technology into a clinical solution to support the improvement of patient ... Innovative Design ... Wireless Solution ...
Breaking Medicine Technology: